Fibromyalgia Recognized as a Disabling Disease by House of Representatives
In a groundbreaking decision, the House of Representatives has unanimously approved six motions recognizing fibromyalgia as a disabling disease. This move not only acknowledges the complexity of this syndrome but also aims to provide essential support and assistance to patients suffering from fibromyalgia.
The approved motions commit the government to recognizing fibromyalgia as a chronic and disabling pathology. Additionally, the government will work towards including fibromyalgia in Essential Levels of Assistance (Lea), ensuring that patients receive the necessary healthcare services without bearing the cost.
Among the commitments outlined in the motions are updates to existing therapeutic protocols, the establishment of a Diagnostic Therapeutic Assistance Pathway (Pdta) for timely and uniform diagnosis, and the creation of a National Registry for fibromyalgia syndrome. Furthermore, information campaigns in collaboration with Regions and associations will be promoted to raise awareness about fibromyalgia.
The recognition of fibromyalgia as a disabling disease has significant implications for affected individuals. They will undergo a medical evaluation to determine the degree of disability, which may lead to access to economic benefits such as disability pensions and carer’s allowance. They will also benefit from specialist medical care and specific treatments covered by the National Health Service.
On the employment front, individuals with fibromyalgia can expect protection against discriminatory dismissal, reasonable adjustments in the workplace, and access to assistance programs to improve their quality of life and independence.
Fibromyalgia is a chronic syndrome characterized by widespread and persistent pain, muscle stiffness, fatigue, and sleep disturbances. It predominantly affects women and can significantly impact their daily and work activities. Diagnosis is challenging due to the lack of specific tests, and symptoms can be similar to other conditions.
The main symptoms of fibromyalgia include widespread musculoskeletal pain, chronic fatigue, sleep disturbances, and cognitive issues. Treatment typically involves a combination of medications, physical therapies, exercise, and stress management techniques. Antidepressant drugs are commonly used to manage symptoms and improve quality of life for individuals with fibromyalgia.
Overall, the recognition of fibromyalgia as a disabling disease by the House of Representatives signifies a step forward in providing support and assistance to those affected by this complex syndrome.